Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Head and Neck Cancer
Interventions
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Combination Product · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Conditions
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
412
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Interventions
bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
2
States / cities
San Francisco, California • Vallejo, California
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
90Y-DOTA-tyr3-OCTREOTIDE
Radiation
Lead sponsor
O'Dorisio, M S
Other
Eligibility
2 Years to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Prostate Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Completed Phase 2 Interventional Results available

FACBC for Recurrent Prostate Cancer

NCT01808222
Conditions
Recurrent Prostate Cancer
Interventions
FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Prostate Cancer
Interventions
atorvastatin calcium, celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Detroit, Michigan • Camden, New Jersey • Hamilton, New Jersey + 1 more
Conditions
Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions
Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
Radiation
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Early Breast Cancer
Interventions
Boost to the tumour bed
Radiation
Lead sponsor
University College, London
Other
Eligibility
Female only
Enrollment
1,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Savannah, Georgia • Detroit, Michigan + 5 more
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
chemotherapy, tipifarnib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
San Francisco, California • Tampa, Florida
Conditions
Neuroblastoma
Interventions
filgrastim, monoclonal antibody 3F8, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, perfosfamide, vincristine sulfate, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy, radioisotope therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Cell Carcinoma of the Bladder
Interventions
vorinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Quality of Life, Small Intestine Cancer
Interventions
bowel obstruction management, quality-of-life assessment
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Interventions
Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Vorinostat, Lapatinib
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
Interventions
5-Azacitidine, all trans retinoic acid, Lupron
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Not applicable Interventional

Intraoperative Radiation Therapy (IORT) in DCIS

NCT03216421
Conditions
Breast Cancer, Ductal Carcinoma in Situ
Interventions
Quality of Life Questionnaires
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
121
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 88 more
Conditions
Neuroblastoma
Interventions
beta-glucan, monoclonal antibody 3F8, sargramostim, isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Osimertinib, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • New York, New York + 1 more
Conditions
Colorectal Cancer
Interventions
cetuximab, fluorouracil, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York